一年一度的"东方之约"步入第八个年头，全球目光再度聚焦第八届中国国际进口博览会（进博会）。 作为连续八届参展的全球食品饮料企业，雀巢携旗下多个业务单元亮相，带来覆盖全球12个国家的百余种精选商品，全方位展现其在营养健康升级、产 品创新迭代与"创造共享价值"领域的最新突破，持续为中国消费者传递"优质食品，美好生活"的核心价值。 在宠物经济飞速发展的今天，雀巢宠物护理展区吸引了众多目光。缓解人对猫毛过敏的冠能畅抚猫粮在宠物食用后21天便可起效，能够显著减少过敏 原；专为犬猫设计的高效肠道调理产品冠能活益菌适用于腹泻、肠胀气、应激反应、免疫力低下等多种场景，助力宠物在疾病期恢复食欲。 雀巢健康科学作为全球医学营养领域专家，业务包括医学营养和消费者保健。在此次进博会上，雀巢健康科学展区也展出了丰富的产品，以满足不同人 群的健康需求。其中，儿科过敏线带来具有前沿深度水解技术的肽敏舒、蔼儿舒以及进阶氨基酸配方恩敏舒；儿科医学营养线展示了个性化的营养解决方案 产品，包括小佰太能、小佳膳系列和针对罕见病领域的品牌Vitaflo；成人营养产品线覆盖速熠素、速愈素、佰态能、佳立畅与佳膳悠选，贯穿患者从治疗到 康复的营养管理路径， ...

11月6日，第八届中国国际进口博览会火热进行，食品及农产品展区优质好物集中亮相，成为名副其实 的"人气高地"。 从榴莲无损检测系统，到精准匹配细分需求的医学营养品，再到新西兰企业"组团参展"共享中国市场机 遇，一系列创新产品与合作模式，让展区既彰显科技与健康的消费新趋势，也传递出中国市场的开放活 力。 "经过我们这套系统检测的榴莲，意味着消费者只需扫码就能了解到榴莲的情况，彻底告别'盲盒'式选 购体验。"市舶士品牌负责人杨佳佳介绍，目前该套系统可实现8至12秒检测完成一颗榴莲，"未来，榴 侦探的应用范围还有望拓展至山竹、波罗蜜等更多复杂水果农蔬的检测领域。" 全勤生携小展商"组团参展" 给榴莲做CT，告别"盲盒"式选购 在市舶士展台，一台"安检机"的设备模型引起不少观众驻足——"榴侦探"无损智检系统正模拟演示榴莲 检测过程。这是市舶士带来的核心亮点，也是"榴侦探"首次亮相进博会。 智通财经记者了解到，该套系统融合了计算机断层扫描（CT）与人工智能（AI）图像识别技术，拥有 13项检测与分析功能，能够精准、无损地分析榴莲的重量、房数、出肉率等关键内在品质指标。同时， 每一颗经过检测的榴莲，都将获得唯一的"一物一 ...

进博会自2018年创办以来，已从单一展会平台成长为推动全球贸易融通、践行开放型世界经济的重要载 体，更成为外资企业共享中国发展机遇的"黄金窗口"。对于雀巢而言，这一平台既是集中展示全球创新 实力与全品类优势的前沿阵地，更是深化植根中国战略的核心纽带。 雀巢大中华区董事长兼首席执行官马凯思（Kais Marzouki）表示："从首届进博会至今，我们有幸以连 续八届参展者的身份，深度参与并见证中国高质量发展与高水平开放的进程。中国是雀巢全球第二大市 场，宠物经济、银发经济与健康需求升级等新趋势，为我们带来了增长机遇。雀巢对中国市场的投入不 会停歇，我们将持续链接全球资源，把更多创新产品与服务带入中国，与中国经济同频共振。" 本次展会中，雀巢婴儿营养、惠氏营养品、奈斯派索、进口水、宠物护理、奶品、健康科学均带来重磅 展品，通过多元化矩阵覆盖家庭饮食与健康护理的全场景需求。 11月5日，第八届中国国际进口博览会（进博会）在上海如期启幕，全球目光再度聚焦这座开放枢纽。 作为连续八届参展的全球食品饮料领军企业，雀巢携旗下多个业务单元重磅亮相，带来覆盖全球12个国 家的百余种精选商品，全方位展现其在营养健康升级、产品创新迭 ...

Group 1: Core Insights - Saintong Medical Nutrition, a company specializing in medical foods, has submitted its prospectus to the Hong Kong Stock Exchange, marking a significant move in a niche market that currently lacks publicly listed companies focused on medical foods as their main business [2][3][5]. Group 2: Industry Overview - The target demographic for medical foods primarily includes infants and the elderly, with a promising growth outlook due to an aging population and increasing chronic diseases [4]. - The market for infant medical foods in China is projected to reach 13.5 billion yuan in 2024, accounting for 58.2% of the medical food market [4]. Group 3: Company Performance - Saintong Medical Nutrition's projected revenues for 2022, 2023, and 2024 are 491 million yuan, 654 million yuan, and 834 million yuan, respectively, with year-on-year growth rates of 33% and 27% for 2023 and 2024 [5]. - The adjusted net profits for the same years are expected to be 120 million yuan, 174 million yuan, and 199 million yuan, with growth rates of 45% and 14% for 2023 and 2024 [5]. Group 4: Business Risks - The company heavily relies on a single product line, with allergy prevention products constituting 85.5%, 88.2%, and 90.3% of total revenue from 2022 to 2024, posing a risk if market demand shifts [7][8]. - The medical food sector is highly specialized, and relying on a single business model may limit growth potential, as the market for specific segments like premature infant products is relatively small [9][11]. Group 5: Competitive Landscape - Saintong Medical Nutrition holds a market share of 6.3% in China's medical food market, which is significantly lower than international competitors like Nestlé (44.2%) and Danone (16.3%) [14][16]. - The company faces challenges in brand recognition and market positioning, as it has been operating independently from its parent company, Saint Yuan Group, since 2021 [12][13]. Group 6: Financial Strategy - Despite low R&D investment, the company has declared substantial dividends, totaling approximately 467 million yuan from 2022 to 2024, raising questions about its financial strategy [33][35]. - The company’s short-term liabilities have increased, with net current liabilities reaching 404.5 million yuan by the end of 2024, indicating potential financial strain [38].